CS1 BiAb-BCMA CAR

N/A

Report date: 2025/01/26 18:14:25

Base Information

Drug NameCS1 BiAb-BCMA CAR
Drug Alias NameT-cells expressing anti-CS1 bispecific antibody and anti-BCMA CAR (Cytoimmune Therapeutics)dual anti-CS1 bispecific antibody/anti-BCMA CAR T-cell therapy (Cytoimmune Therapeutics)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionSLAM family member 7 modulatorsTumor necrosis factor ligand superfamily member 13 modulators
TargetsTumor necrosis factor ligand superfamily member 13SLAM family member 7
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCytoImmune Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesCytoImmune Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A